CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 700 enrolled
Drug / intervention
Drug Therapy for Heart Failure +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01920048
NCT01920048N/ACompleted

REVascularisation for Ischaemic VEntricular Dysfunction (REVIVED): a Randomized Comparison of Percutaneous Coronary Intervention (With Optimal Medical Therapy) Versus Optimal Medical Therapy Alone for Treatment of Heart Failure Secondary to Coronary Disease

King's College London·interventional·Posted Aug 9, 2013·Updated May 31, 2022

In Brief

A clinical study evaluating Percutaneous Coronary Intervention, Drug Therapy for Heart Failure, and 1 other intervention for Ischemic Cardiomyopathy. Completed, enrolled 700 participants across 40 sites.

Detailed Summary

This study will assess whether percutaneous coronary intervention (angioplasty of the heart arteries) can improve survival and reduce hospitalization in patients with heart failure due to coronary disease, who have been treated with the best contemporary medical therapy.

Study Details

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 9, 2013
Enrollment StartAug 28, 2013
Primary CompletionMar 19, 2020
Study CompletionMar 31, 2022
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 12.9 years ago

Interventions

Percutaneous Coronary Interventionprocedure

Drug Therapy for Heart Failuredrug

The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines

Device Therapy for Heart Failuredevice

The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.